Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph III Inotuzumab Ozogamicin To Frontline Therapy In Young Adults With Newly Diagnosed Precursor B-C

Protocol: ALLIANCE-A041501

Full Title

A Phase III Trial To Evaluate The Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-Cd22monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Leukemia Chronic Lymphocytic Leukemia